Podcasts about GSK

Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty to unpack for the industry as it heads into fall. Greater clarity on President Donald Trump’s tariff and pricing strategies has likely come as something of a relief for those companies operating in the U.S., but that news was tempered by a shutdown of the federal government on Wednesday. Meanwhile, big changes are likely on the way at GSK, whose longtime CEO Emma Walmsley is headed for the exit. In this week’s episode of "The Top Line," we break down some of the biggest stories across Fierce Pharma for the week—which may very well be some of the biggest stories of the year—touching on critical policy updates in the U.S., the furloughing of federal employees at agencies like the FDA and NIH and the imminent departure of GSK’s chief executive. Fierce Life Sciences’ Ben Adams sits down with Fierce Pharma's Fraiser Kansteiner to discuss the latest headlines and go over the key points from each major development that has played out. To learn more about the topics in this episode: FDA avoids the worst amid government shutdown, but new applications put on hold NIH research grinds to a halt as government shuts down Pfizer offers price concessions, $70B US outlay in Trump's 'most favored nation' push Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels See omnystudio.com/listener for privacy information.

Chinmay Sharma | HR Business Leader, Performance Emerging Markets ,GSKChinmay is an HR leader with 22 years of diverse experience in organizations like Procter & Gamble (2003-2012), Philip Morris International (2012-2020) and Glaxo Smithkline (Dec 2020 – till date)Chinmay has done roles across HR domains (Factory HR, Rewards, Talent Acquisition, Business Partnering) at Country, Region and Global level. He is very passionate about driving change and has a successful track record in shaping inclusive, diverse and performance driven work cultures by developing people and helping them identify their purpose in alignment with the company vision. He is also an accomplished coach focusing on enhancing personal leadership and performance effectiveness. He was recognized by HRD Asia magazine as “Top 20 Asia HR Directors in 2020” and “India's Most Impactful CXOs” by ET Now in 2023.Chinmay is currently transitioning to a new role as HR Business Leader for Performance Emerging Markets for GSK and is in process of relocating to London. Prior to this, he was the CHRO for GSK India where he successfully led the cultural transformation of a 100 years legacy company to become an agile, innovative and technology driven organization with thriving talents and leaders.Chinmay has lived and worked in India, Malaysia, Hong Kong and Switzerland. He got educated at Rajasthan University, Jaipur; SCMHRD (Symbiosis, Pune) and Cornell University, New York. He enjoys playing Tennis, listening to Indian semi-classical music & loves reading autobiographies. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for specific operations to optimizing the entire production process. Additionally, Crystalys, backed by Novo, has debuted with $205 million to tackle gout with its drug dotinurad. The FDA recently singled out Aurinia Pharmaceuticals in a LinkedIn post about surrogate endpoints for lupus nephritis drugs, criticizing companies for not conducting post-approval studies to demonstrate benefits on hard clinical endpoints. Larimar's Friedreich's ataxia drug has faced concerns about anaphylaxis, causing shares to fall. GSK's CEO Emma Walmsley has stepped down after 9 years, resealing pharma's glass ceiling. Upcoming webinars will focus on topics such as mRNA medicine and biopharma in an age of deregulation.

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year's fifth largest—came just a week after Pfizer acquired rising obesity star Metsera for $4.9 billion. Just seven days later, Metsera made the New York–based pharma look like a genius with mid-stage data for one of the deal's centerpiece therapies, MET-097i, showing 14% placebo-adjusted weight loss over 28 weeks.After months of tarrying and threats, President Donald Trump announced last week that 100% tariffs would take effect Oct. 1—with broad exceptions for companies that have taken steps to build out their domestic manufacturing footprints. One company that has answered that call—as well as a letter sent by the president to 17 of the largest pharma companies requesting action on his most-favored-nation drug pricing policy—is Pfizer. In a joint oval office announcement with Pfizer CEO Albert Bourla and HHS officials, Trump said Pfizer would offer all new medicines at MFN prices.Meanwhile, over at the FDA, CDER Director George Tidmarsh, who has flown relatively under the radar since taking the post in July, took to LinkedIn to address the subject of relying on surrogate endpoints in drug approvals. In a since deleted post, Tidmarsh called out Aurinia Pharmaceuticals' lupus drug as an “egregious” example of this phenomenon. CDER's sister agency, CBER, also made a splash last week, publishing three draft recommendations intended to accelerate the development of cell and gene therapies.Speaking of CGT, maybe the biggest clinical development news of the year emerged from this space last week when uniQure announced that its gene therapy for Huntington's disease, AMT-130, slowed disease progression by 75% after three years. With these data in hand, uniQure plans to file for FDA approval of the treatment in the first quarter of 2026. If successful, AMT-130 would be the first genetic therapy for the intractable neurodegenerative disease.Finally, biopharma's glass ceiling just got a little more tightly sealed. Emma Walmsley, the industry's first female CEO, is stepping down after nine years at GSK, handing the reins to current chief commercial officer, Luke Miels. When Walmsley officially departs on Dec. 31, she will leave Vertex CEO Reshma Kewalramani and incoming Takeda CEO Julie Kim to represent the sisterhood at the highest ranks of the biopharma industry.

Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech's largest step toward marketing its own pipeline. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the evolution of Genmab, which, for many years, relied on a partnership model that delivered blockbuster revenues but now is making a change as a patent cliff looms.The analysts also assess the tenure of Emma Walmsley the longtime CEO of GSK, and what's next for the U.K. pharma under incoming CEO Luke Miels. Turning to the U.S., Washington Editor Steve Usdin discusses President Donald Trump's looming tariff threat on imports of branded drugs, which Usdin says would hurt small biotechs the most. Usdin also analyzes the response of multinational pharmaceutical companies to the president's demand that they make “most favored nation” price concessions, now that Monday's deadline has passed. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/657131#biotech #pharma #deals #FGF21 #MASH #Interleukin5 #asthma #PhRMA #PBM #tarriff #MFN00:01 - Sponsor Message: IQVIA Biotech02:26 - Genmab's Merus Buy09:43 - CEO Switch at GSK17:22 - Trump Tariff Threat21:17 - MFN Drug PricingTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

The 5 things you need to know before the stock market opens today: Jeep-maker Stellantis has a new CFO, the CEO of British drugmaker GSK is stepping down, SEC Chair Paul Atkins is moving to fast track President Trump's effort to shift the earnings report schedule for public companies, Vice President JD Vance has spoken publicly about TikTok, and Bad Bunny will headline this February's Super Bowl halftime show.  Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Jim Cramer and David Faber led off the show with the deal the day: Videogame publisher Electronic Arts has agreed to be taken private by Silver Lake Partners, Affinity Partners and Saudi Arabia's PIF  in a $55 billion buyout. The anchors reacted to comments by Walmart CEO Doug McMillon, who was quoted as saying "It's very clear AI is going to change literally every job." Changes in the C-suite: New CEOs at CSX,  Barrick Mining and GSK, while Comcast named its President Mike Cavanagh to join Brian Roberts as Co-CEO effective January 2026. Also in focus: Markets and government shutdown watch,President Trump reiterates his threat to impose 100% tariffs on movies filmed outside of the U.S., Jim's new book "How To Make Money In Any Market" goes on sale Tuesday. Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nueva dimisión en Stellantis: el director financiero, Doug Ostermann, deja su cargo y será reemplazado de manera inmediata por Joao Laranjo, veterano de Fiat Chrysler Automobiles, la empresa predecesora de Stellantis, quien se reincorporó este año como director financiero para Norteamérica. GSK anuncia el nombramiento de Luke Miels como CEO, con efecto a partir del 1 de enero de 2026. Otra farmacéutica, AstraZeneca planea cotizar directamente en la Bolsa de Nueva York sin dejar Londres. El Indicador de Sentimiento Económico mejora en septiembre ligeramente en la eurozona al situarse en 95,5 puntos, dos décimas más, según los datos del índice elaborado por la Comisión Europea, que sitúa a España a la cabeza entre las mayores economías de la UE. Hablaremos de retribución flexible con Ignacio Sanz Alonso, subdirector de Colectivos de Mapfre Vida. Y los temas de la actualidad los debatiremos con Isabel Giménez, directora de la Fundación de Estudios Bursátiles y Financieros.

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview three high school students who made less invasive EoE diagnostics the focus of a science fair project. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:51] Co-host Ryan Piansky introduces the episode, brought to you thanks to the support of Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:08] Holly introduces today's guests, three high school students from Texas who made EoE diagnostics the focus of a science fair project: Leyna, Nhu, and Jaden.   [1:47] Leyna, Nhu, and Jaden are best friends. Nhu was diagnosed with EoE last summer. Leyna said Nhu told them it took a long time for the doctors to diagnose her because they thought it could be different conditions.   [2:07] Nhu told them about her appointments and her endoscopy procedures. She had to miss school sometimes. Leyna and Jaden were concerned for her.   [2:22] Leyna took AP Bio. Her teacher was a sponsor for the science fair. Leyna thought this would be a meaningful project for the three friends to learn more about Nhu's condition.    [2:45] Holly shares that she wasn't diagnosed until her 20s, but she was sick for much of her childhood.   [3:13] Ryan shares that he was diagnosed when he was two, after two years of his parents taking him to different doctors and undergoing different tests.   [3:31] Nhu says it was hard to find a specialist. They found one and had to wait six months for an appointment. It was a long time, suffering from the effects of EoE with constant symptoms, a lot of heartburn, and painful vomiting.   [4:00] Nhu was diagnosed with EoE in her sophomore year of high school. Her friends have seen her endure a lot, but she's strong. Nhu had to miss an orchestra concert where she had a big solo, because of her EoE.   [4:32] Doctors thought Nhu could have something different, like H. Pylori or cyclic vomiting syndrome. They didn't have clear answers, which was confusing and frustrating for her family.   [4:50] Holly talks about how difficult it was for her to get a diagnosis, and how she was told she was vomiting to get attention. She shared her reaction when diagnosed. She would like someone to do a research study about the pain tolerance of people with EoE.   [5:41] Leyna says junior year is the hardest year of high school. She doesn't know how Nhu survived physics and AP classes with EoE on top of it, and making up late work.   [6:14] Nhu takes a weekly injection. Her symptoms happen almost monthly. Sometimes she misses school for two weeks and has to catch up on work. Leyna and Jaden help her with her schoolwork.   [6:47] Ryan shared how he missed a third of his senior year in high school. He's now on an injectable biologic that has helped him a lot. That treatment option wasn't available when he was in high school. Having supportive friends to send him his schoolwork and keep him up-to-date was very helpful.   [7:11] Ryan explains the esophageal string test (EST). This is a tool that was developed to help monitor eosinophilic esophagitis (EoE). The test works by having the patient swallow a capsule about the size of a Tic Tac that has a string attached.   [7:25] The capsule dissolves in the stomach while the string stays in place in the esophagus. After about an hour, it's gently removed. Along the way, the string collects samples from the lining of the esophagus, which are reviewed, similarly to a biopsy.   [7:37] Holly adds that what makes the string test unique is that it doesn't require an endoscope, anesthesia, or recovery time, things that usually come with a traditional endoscopy and biopsy.   [7:46] It's now being used with patients as young as four years old. While some people might feel some minor discomfort, it's generally much easier for regular monitoring than an endoscopy.   [7:57] Holly explains that she was involved in testing the device and developing a swallowing protocol for it at Children's Hospital of Colorado. We will talk more about this later in the episode.   [8:06] Ryan adds, to learn more about the development of the string test, listen to episode 26 of this podcast.   [8:10] The string test is one of multiple, less-invasive monitoring tools for eosinophilic esophagitis. Others include the sponge test and unsedated trans-nasal endoscopy.   [8:19] To learn more about unsedated transnasal endoscopy, listen to episodes 19 and 20, where we talk to clinicians and patients about this method.   [8:27] During that episode, we talked to the developers of the EST.   [8:38] Jaden tells how he, Leyna, and Nhu brainstormed ideas and decided to base their project specifically on how to diagnose EoE in a less invasive way than endoscopies.   [9:12] Before this project, they were not familiar with the EST. Nhu says her only option for diagnosis was an endoscopy.   [9:21] Holly says it's still like that in Maine. She came from an area of the country where the EST was researched, and it's interesting to her that she doesn't have access to it now.   [9:37] What appealed to the group about the EST as an alternative to endoscopies is that it was so different. There are so many advanced technologies, and the EST is just a capsule taped to a string. It is simple but innovative.   [10:13] Real Talk: Eosinophilic Diseases had Drs. Robin Shandas and Steven Ackerman, who were instrumental in the development of the esophageal string test, as guests on episode 26 of this podcast. Ryan encourages listeners to check out that episode at apfed.org/podcasts.   [10:42] They searched for keywords and analyzed a variety of scholarly literature. They collected a lot of data from Dr. Ackerman's papers.   [11:10] They also reached out to gastroenterologists on social media. A hard thing about science fair projects is coming up with an experiment. They didn't know what they could do just with compiled research, but they had a great sponsor who helped along the way.   [11:56] Leyna says they trusted that the doctors they reached out to on social media were competent in their understanding of different diagnostic methods. She notes that different locations may have different resources and different biases.   [12:14] Leyna says they talked to doctors in the U.S. and from different countries, including India and Mexico. She commented that communities in Mexico might not have the same resources as communities in the U.S. or India. That might change their understanding of the EST.   [12:33] We might have different biases because we don't have the same technology to research and find the same things about the EST.   [13:12] Leyna says they reached out to doctors on social media, but didn't get responses from that many doctors. Reaching out to patients would be a good thing if they want to continue the project.   [14:00] Jaden says most of the data they found was from Dr. Ackerman, including a survey he did comparing the data of the EST and the biopsies.   [14:10] They found that the EST and the biopsies were relatively similar in terms of discovering the eosinophilic count and determining whether the EoE is active or inactive.   [15:30] They found differences between ESTs and biopsies in finding how much of a certain chemical is in the patient's cells.   [14:43] Leyna comments that one of the doctors they reached out to told them about the sponge test, another less invasive method. They didn't research the sponge test, but it sounded interesting.   [15:00] Ryan says there are a lot of cool new techniques that are being researched, like the transnasal endoscopy that goes in through the nose, the string test, and the sponge test.   [15:13] Leyna says the cool thing was hearing about all these methods. They had hypothesized that there are less invasive methods that may be better than endoscopies.   [15:27] They were not able to prove their hypothesis yet. They learned a lot of different things that could be beneficial.   [15:42] Holly points out that the transnasal endoscopy is not scary. It's also known as the unsedated endoscopy. Holly has done both the EST and the unsedated endoscopy,  and they each have pluses and minuses.   [16:15] Nhu explains how the team would meet at one of their houses, usually Leyna's house. One day, they watched Interstellar together, and the “Eureka moment” scene motivated them.   [16:41] They helped each other whenever necessary. When the project board was due, they all went to Leyna's house to work on the project board. They worked together as a team.   [16:51] Jaden analyzed a lot of the data. Leyna reached out to professors. Nhu helped Jaden understand some terms. On the day they presented the project, Nhu was sick in the hospital, which made them sad. They included a photo of her on the project board.   [17:28] Holly says that although Nhu wasn't there, it may have helped people know how sick EoE can make you feel.   [18:28] Leyna says one of the doctors they reached through social media told them that endoscopies have lots of benefits. The biopsy samples give healthcare professionals a clear idea of how many eosinophils per high-powered field, a key indicator in diagnosing EoE.   [18:57] The diagnosis gives a baseline for starting treatment for the patient, monitoring how effective the treatment is. You can't count the number of eosinophils per high-powered field using the string test.   [19:11] The EST is a gelatin capsule attached to a long string that you swallow. It dissolves in the stomach. It's less expensive than an endoscopy.   [19:33] Holly says one of the big differences is that you can't diagnose EoE on a string test. It has to be diagnosed with an endoscopy.   [19:40] Leyna says they learned that from the doctors and medical students who reviewed their project board. You can't diagnose EoE with the EST, but you can monitor it.   [19:52] The string test doesn't provide a direct eosinophil count, but it reflects the level of inflammation in your esophagus, and it can measure the protein biomarkers. That correlates with the eosinophil count from a biopsy. It is good for monitoring EoE.   [20:12] Ryan says that's a great idea. In the show notes, there is a link to the diagnostic consensus guidelines. They specify that you need an endoscopy and 15 eosinophils per high-powered field to be diagnosed with EoE.   [20:28] The EST can monitor the progression of the disorder as you're trying new medicines or an elimination diet. If you need an endoscopy every three to six months, it can be taxing.    [20:49] Ryan comments on the cost. Going through anesthesia for an endoscopy is very expensive, and not everyone has the insurance to cover these diagnostic procedures. The EST is an option you can do in a doctor's office in just over an hour.   [21:16] Holly asks if Nhu has participated in a string test. Nhu has not, but she would love to do a string test if she had the chance. Whenever she sees her doctor, she brings up her condition, and what could be better for her, such as the string test.   [22:06] The science fair is a huge regional fair in Houston, called the Science and Engineering Fair of Houston (SEFH). This was their first year participating. They were regional qualifiers from their district. When they got there, everyone else had six-foot-tall printed boards. It was a shock to them.   [22:56] They hope to level up their board for next year's fair. It was cool and eye-opening to see all these student researchers and get feedback from the people who walked by their booth. They heard some interesting things to use in their next project.   [23:15] One medical student in attendance came by their project board and suggested that while the EST may not diagnose EoE, maybe it could be used as a screening tool [to help identify people who should follow up with a gastroenterologist for a diagnostic work-up]. Interestingly, this was a medical student, and she had recently scheduled an appointment with a gastroenterologist for an endoscopy to see if she has EoE.   [24:04] This student didn't seem to know much about EoE, but felt she was experiencing symptoms that might indicate EoE. She told them she had learned so much from their board. Ryan says it's great that the project was able to help this person.   [24:44] Jaden says that the students at their school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE and how the EST could change a lot of things as a screening method.   [25:11] Jaden says their science teacher came by to see their board and how they were doing. He liked how they included not only the research information but also the stories of why they chose their project and why they were passionate about it.   [25:34] The day of the project, Leyna and Jaden were sad that Nhu couldn't be there with them. Their sponsor, Leyna's biology teacher, was sick, but showed up at the fair to view their presentation. They raised awareness about EoE. People learned about it.   [25:54] When Nhu told Leyna about her EoE, Leyna had no idea what it was. She's glad their project brought the issue to the table. They emphasized that more research needs to be done. There is much we don't know about less invasive methods.   [26:23] Nhu has considered a career in medicine since she has been in many hospitals and talked to a lot of doctors. Jaden sees himself in the engineering field, but he enjoys researching like this and seeing things through a different perspective.   [27:05] Nhu learned a lot about herself with EoE. Leyna loves how much they learned from this project. She is interested in pursuing scientific research. She thinks it's cool that Ryan is a graduate student.   [27:24] Leyna just got back from a five-week summer research program. It was insightful. She doesn't see herself becoming a doctor, but possibly doing research and advocating for different conditions.   [27:43] When Ryan was in high school, with all his hospital time, he had an interest in medicine, then he took a turn into engineering. He enjoys research. He's passionate about engaging in patient advocacy work through APFED.   [28:10] Ryan is glad for Leyna, Nhu, and Jaden that they were able to engage with this research and do it as a group and as friends. He says it's fantastic to hear from the group about the whole process they went through.   [28:23] Holly asks, looking back on everything you guys learned and experienced in this project, what's one question or idea you would still like to explore if you had more time and resources?   [28:38] Nhu wants to research finding more ways to diagnose EoE. Testing for EoE and finding EoE are very interesting for her.   [28:53] Jaden thinks that if they had more time, they would try to create a model of the EST to show how it works. He would possibly try to improve upon the model or develop something new. Instead of just relying on the data we have, he would try to collect data.   [29:26] Leyna agrees. She would like to build a prototype, understand how the capsule works, and find out whether the string down the esophagus is uncomfortable.   [33:41] Ryan suggests there is a doctor who would let them try the string test so they could see how it feels. Holly tried the string test at a major children's hospital while it was being researched. She doesn't want to ask her patients to do something she hasn't done, since she has the diagnosis too.   [30:37] Ryan comments that he enjoyed hearing about the process of the project.   [30:51] Ryan gives a quick recap: The esophageal string test is a tool to help monitor EoE. It is not a tool to diagnose EoE. If you or a loved one has EoE or suspect that you might, ask your clinician about the string test to see if it's an option for you.   [31:03] Holly adds: School science fairs are one way to bring education about eosinophilic disorders to schools. We love hearing about community science fairs and school projects that teach others about these conditions.   [31:13] For those of you looking to learn more about eosinophilic esophagitis, we encourage you to visit apfed.org/EoE.   [31:23] For those looking to find specialists who treat EoE, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [31:30] Ryan thanks Leyna, Nhu, and Jaden for joining us today. Holly also thanks APFED's Education Partners Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Dr. Robin Shandas Dr. Steven Ackerman “Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference”   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of Bristol Myers Squibb, GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   “Nhu and Jaden are my best friends. Recently, Nhu was diagnosed with EoE. I remember her telling us about the long diagnosis process. It took the doctors quite a long time to diagnose her because they thought it could be different conditions.” — Leyna   “I thought that this would be a meaningful project for us to learn more about Nhu's condition [of EoE].” — Leyna   “The students at our school didn't know much about EoE, but when they looked at the project board, they were shocked by how incredibly difficult it is to diagnose EoE.” — Jaden   “One of the main benefits of the string test is that endoscopies can be quite expensive, especially the anesthesia. It could be beneficial for people who don't have the money for an endoscopy.” — Nhu

Ochelli Effect 9-25-2025 SNAFU NEWS OVERNIGHTActually went LIVE 530 AM EasternJust to get on it ahead of tomorrows shorts X Mess, and firestorm meltdowns , here we go...Let's start with a typical Americans target something that makes no sense because someone wants you to believe an unproven motive you may have forgotten from June of this year. NOTE all The MSM agree to play the BS Motive game especially when COPS who NNNEEEEEVVVVEEERRRRR Lie present BS without investigation or the narrative they or those that support them enjoy. We report, we decide and you keep buying it, should be the American MSM mantraLPhotos show Waymo vehicles on fire during LA protests as company cuts downtown servicehttps://www.cnbc.com/2025/06/09/photos-waymo-fire-la-protests.htmlRWaymo cars set on fire as Los Angeles immigration raids protests continuehttps://www.foxla.com/news/waymo-cars-fire-los-angeles-immigration-raids-protestsNow think critically if you can?Ochelli SEZ The Grouypers Strike againWitnesses say there were intentional pauses between shots that seemed as though targets were selected carefully and if true aside from bullets strikes the building all bullets landed on Detainees NOT ICE COPSGunman wrote 'ANTI-ICE' on unused bullet in fatal attack on Dallas immigration officehttps://www.reuters.com/world/us/three-injured-shooting-ice-facility-dallas-local-media-reports-2025-09-24/THE THING THEY SLIP BY YOU ON AUTISM WHILE IDIOTS ARGUE OVER HOW EFFECT or DESTRUCTIVE TYLENOL IS = THE NEW QUID PRO OR QUO THAT IS A BRAND NEW SHINY FDA APPROVAL FOR A LEGACY DRUG COMPANY THAT CHANGED IT's NAMES and MERGERS with MERGERSGSK plc is a publicly traded company, so it is owned by its shareholders. Major shareholders include institutional investors like The Vanguard Group, BlackRock, and Schroder Investment Management Ltd.. The company was formed in 2000 by the merger of Glaxo Welcome and SmithKline Beecham, creating a multinational pharmaceutical and biotechnology company headquartered in London.RIGHT AFTER THE SILENT DEAL CUT AS REAL REPS OF CORPOARTION AMERCAN DREAM ALLOWED TRUMP TO EAT (whatever they hell they served) OVER AFTER HIS PLATDATE WITH LESSER ROYAL CHARLES in WINDSOR where EPSTEIN IMAGES bounced off the wall DOUBLED THE DISTRACTION. AFTER ALL every devil knows IN PERSON is the only way you TO SELL LIVES OR SOULS. FDA, in unusual step, aims to repurpose old GSK drug as autism treatmentAfter reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling more than two decades ago — for a condition associated with autism.https://www.biopharmadive.com/news/fda-gsk-wellcovorin-leucovorin-autism-cerebral-folate-deficiency/760840/So a little false hope and a bottle of lame alleged vitamins land on the hot shelf, and Ochelli bets A.J. is pissed he didn't get in on that medicine showhttps://www.newsnationnow.com/health/what-leucovorin-treat-autism/AS THE WORM TURNS... in RFK Jr's Brain I guess...---IN OTHER SPORTS and WWE R THE WORLD HIGHLIGHTSMLB is now going to the Video game Style ABS system for making sure Balls and Strikes get called without having to factor in Umpire Bias. Too bad they are about 30 years late on that. Also too bad we can't have a BS meter on any screen where American Politicians open their mouths!https://www.mlb.com/news/abs-challenge-system-mlb-2026Press Secretary Leavitt alleged intentional sabotage by UN staff after an escalator stopped while the Trumps were on it and a teleprompter failed during the president's speech. https://www.facebook.com/photo.php?fbid=3493045087501295&set=a.101711856634652&type=3AND IF YOU CAN'T ACCEPT FED-BOOK I know you'll accept FOX NEWSFox News host Jesse Watters says the US should bomb the UN over Trump's broken escalatorhttps://www.the-independent.com/tv/news/trump-escalator-un-bomb-us-jesse-watters-video-b2832888.htmlIf you give a toddler an army and nuclear code He will get some Ice Cream.Orange Jesus already delivered his BS to the U.N. before FOX even had time to start Griping and casually suggesting eliminating those who dare defy LORD TRUMPFact-check: Trump misleads about ending 7 wars, US economy, renewable energy in UN speech https://www.politifact.com/article/2025/sep/23/trump-un-general-assembly-speechIf YOU GASLIGHT THE GASLIT HOW MANY FIRES DOES A GASLIGHT LIGHT IF A LIGHT COULD BE BRIGHT?Italy sends warship to accompany Gaza flotilla following Israeli attackhttps://www.middleeasteye.net/news/footage-shows-apparent-attack-gaza-bound-global-sumud-flotillaBTW no article or REFERENCE LINKS but Jay Z has a lot of rumored issues with allegations flying about Paternity, Connections to Puffy, Underage Partners, Hush Money, Divorce, and Maybe getting Too much Destiny out of Beyonce's Besties in Destiny's Child. So Plenty of Drama that maybe has an In Law Mama keeping the facade of a hip-hop pop empire intact.From the bottom of The Ochelli Heart, Even though I see Black Twitter, and Respect 50 Cent, I just can't bother to care, except I miss when this might have been the scandal that was the why is America so stupid international Press I just can't muster the energy to give a full shit. Government Shutdowns Q&A: Everything You Should Knowhttps://www.crfb.org/papers/government-shutdowns-qa-everything-you-should-knowFROM THE KIMMEL KENNEL Trump slams Kimmel's return: "We're going to test ABC out on this"https://www.axios.com/2025/09/24/trump-jimmy-kimmel-return-abcWhat Really pissed off Donald?Jimmy Kimmel's first show back on September 24, 2025, drew approximately 6.26 million viewers, a significant increase from his previous average of around 1.77 million viewers in the second quarter of 2025. This represents a viewership increase of roughly 250% compared to his recent average, making it the show's highest-performing regularly scheduled episode in over a decade.and that was just his LIVE viewers without all of the regular channels participating.Meanwhile Southpark Pussyed out last week in the hot kitchen then released "Conflict of Interest" EPISODE 5 of the current season into LOOney Tunes Lame 2025. Spoiler, It wasn't worth talking aboutwebelos kid Maybe a dude or a chickPrediction Marketing Betting AppsGazza Satan and Trump are having a baby Trump makes a little PLAN B SoupApps and Undue Influence Via Social MediaKyle's Mom is gonna Strike Gazza MaybeI wouldn't want to be a hospital in PalestineALSOIT'S FAT BEAR WEEKhttps://www.theguardian.com/us-news/live/2025/sep/25/donald-trump-james-comey-fbi-ice-texas-latest-us-politics-news-updates-liveFormer FBI director James Comey expected to be indicted on criminal charges, reports say – US politics liveCharlie Kirk https://www.youtube.com/shorts/BGRhw0C7JL0Mark Cubanhttps://www.youtube.com/shorts/x7AuftuT04wA Very Strong Case https://www.youtube.com/watch?v=KrU6F-S8VMo---BE THE EFFECTEmergency help for Ochelli and The NetworkMrs.OLUNA ROSA CANDLEShttp://www.paypal.me/Kimberlysonn12 new Social Media experimentsBLUESKYhttps://bsky.app/profile/ochelli.bsky.socialTRUTH SOCIALhttps://truthsocial.com/@Ochelli---NOVEMBER IN DALLAS LANCER CONFERENCEDISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/Coming SOON Room Discount Details The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201BE THE EFFECTListen/Chat on the Sitehttps://ochelli.com/listen-live/TuneInhttp://tun.in/sfxkxAPPLEhttps://music.apple.com/us/station/ochelli-com/ra.1461174708Ochelli Link Treehttps://linktr.ee/chuckochelliAnything is a blessing if you have the meansWithout YOUR support we go silent.---NOVEMBER IN DALLAS LANCER CONFERENCEDISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/Coming SOON Room Discount Details The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201. easy access to Dealey Plaza

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The FDA is working to reapprove GSK's long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developmental delays with autistic features.” This immediately followed a much-anticipated press conference in which President Donald Trump, flanked by Health Secretary Robert F. Kennedy Jr and other healthcare administrators, linked the use of Tylenol during pregnancy to rising rates of autism.  Meanwhile, Pfizer woke us all up Monday with the news that it had acquired breakout obesity rockstar Metsera for $4.9B. The deal should pump new life into Pfizer's portfolio, which over the last two years has suffered three discontinued assets. Bite-sized deals—or those at or below the $5 billion mark—have defined biopharma recently, with Roche picking up metabolic dysfunction-associated steatohepatitis biotech 89bio for a potential $3.5 billion last week and Novartis putting another $5.7 billion on the line with partner Monte Rosa Therapeutics in a second molecular glue agreement.  Another therapeutic space primed for M&A action is psychedelics. After AbbVie bought Gilgamesh Pharmaceuticals' lead depression asset for $1.2B last month, BioSpace spoke sought opinions from experts on who might be next to take the plunge. A few potential names included Eli Lilly, Bristol Myers Squibb and Merck.  On the policy front, the CDC's revamped vaccine advisory committee convened for their first meeting to discuss COVID-19, MMRV and hepatitis B vaccine schedules. Industry watchers who spoke to BioSpace commented on the “lack of knowledge” and dearth of previous experience on the committee. And while the advisors ultimately voted to change the schedule for the MMRV vaccine, it appears unlikely to significantly affect manufacturers' bottom lines. Finally, in rare disease, Stealth BioTherapeutics secured its long-sought approval for elamipretide—now Forzinity—in Barth syndrome—a disorder that would fall under the purview of the FDA's new Rare Disease Evidence Principles framework for ultra rare diseases affecting less than 1,000 people in the U.S. And we said “Bye Bye Bluebird,” as the famed gene therapy biotech—which was recently bought out by two private equity firms—returned to its original moniker, Genetix Biotherapeutics.  Lastly, make sure to sign up for Biopharm Executive here for access to a special deep dive into China biopharma.  

In Episode 43, of Season 5 of Driven by Data: The Podcast, Kyle Winterbottom was joined by Sarah Hardison. Product Director, Analytics Enablement at GSK where they discuss the results from a research project on the investment and value in Data and AI that was conducted to support an MBA Thesis in partnership with University of Cambridge, which includes;Why aligning data and AI initiatives with overarching business strategy is the most critical factor for success, with 80% of respondents citing it as essential to delivering value.How failing to measure value directly correlates with an inability to demonstrate impact. All organisations that had not shown value also reported not tracking any metrics.Why only 50% of surveyed organisations reported actively measuring the value of their data and AI initiatives, despite it being foundational to demonstrating return.How 65% of participants believed they had successfully demonstrated value. The remaining 35% had not, and all of those lacked measurement frameworks.Why cost reduction and revenue generation were reported as the primary ways value is defined, yet only a few sectors could clearly demonstrate revenue impact.Why metrics such as customer satisfaction and innovation are harder to quantify but still considered essential soft indicators of value.How the perceived value of data as an asset varies depending on business context and use case, making standard valuation challenging.Why telling success stories and communicating achievements across the business was identified as a critical enabler for cultural adoption and stakeholder engagement.How incremental delivery through proofs of concept helps secure long-term value and supports agile execution.Why business cases are more compelling when they include both financial metrics and alignment with strategic objectives.How the cultural orientation of a company, whether strategy-driven or metrics-driven, should guide how data leaders approach value articulation.How networking internally and understanding business pain points leads to more relevant and supported data solutions.Why data's value is similar to that of brand equity, being intangible, influential, and entirely context specific.For more information on our upcoming Driven by Data LIVE event;...

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 19, 2025. In this episode: GSK announces US investments during Trump's UK visit; Lilly thinks twice about UK lab investment; analyzing the rise in China R&D and deals; Regeneron CEO on his company's ignored blockbusters; and AstraZeneca's COPD trial failure. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-D4VJFG2XNJGAJEFGSXNEQUA3BU/ Sign up for China R&D webinar: https://www.citeline.com/en/events/china-transforming-pharma This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The FDA Group's Nick Capman speaks with Catherine Lunardi, Founder and CEO of GenAIz. With nearly a decade leading GenAIz and prior leadership roles at GSK, CGI, and Héma-Québec, Catherine brings a seasoned perspective on how life science organizations can practically and compliantly deploy AI to build the next generation of labs.Catherine explains the biggest challenges labs face today—like fragmented data, manual processes, and costly compliance reviews—and how AI can help orchestrate data, surface anomalies, and accelerate insights without replacing the people at the center of science. She outlines a step-by-step approach to identifying the right challenges, aligning AI projects with company strategy, piloting solutions with clear ROI, and managing change so teams embrace and sustain new tools.Nick and Catherine also discuss the balance between innovation and regulation, how to keep humans in the loop, and why strong governance and explainability are essential to ensuring AI adds real value in GLP environments.About The FDA Group: The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations: ⁠https://www.thefdagroup.com/

Sir Jon Symonds, Chair of GSK was Bina's first guest when Pull up a Chair launched in 2022. Three years on, Jon returns to give an update on what the world has learned since: geopolitically, economically and technologically. Can health systems do more than just treat sickness? Hear the highlights from their conversation in under 10 minutes. This episode is part of Pull Up a Chair's ‘Insights' series, featuring bite-sized perspectives and advice from podcast guests.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of their GLP-1 weight loss drugs in advertising, particularly during a prime time special with Oprah Winfrey. Lilly is also investing in a $5 billion manufacturing plant in Virginia, part of a larger $27 billion U.S. investment plan.In other news, GSK is committing $30 billion to boost R&D and manufacturing operations in the U.S., showing a strong commitment to innovation. Additionally, advancements in AI-driven antibody discovery technology by Sino Biological are revolutionizing the field of biotechnology. The pharmaceutical industry is facing tightening oversight and regulatory changes, as well as exploring predictive care powered by consumers and AI technology.This dynamic landscape highlights the importance of staying informed and adaptable in the ever-evolving world of Pharma and Biotech.

President Trump's state visit to the UK has coincided with a flurry of multi-billion investments in British tech industries. But among the good news, there's money travelling in the opposite direction, with UK pharma giant GSK announcing massive investment in the US. And, for the UK steel industry there's disappointment, as hoped-for cuts to tariffs on UK exports to the US come to nothing. Sean Farrington looks and what's coming in, what's going out and what's staying the same with Microsoft CEO Satya Nadella and expert voices from the UK steel industry and the financial markets.

Miércoles clave en los mercados globales: la atención está puesta en la Reserva Federal y las nuevas señales de política monetaria, mientras empresas de tecnología, banca y entretenimiento protagonizan movimientos importantes:

What does it take to lead successful drug development—whether at a global pharma giant or a small biotech start-up?In this episode of SNiPs, Dr. David Krause joins Bracken CEO Dr. Colin Miller to reflect on three decades of experience spanning large organizations like GSK to fast-moving start-ups. From aligning clinical development with medical affairs to serving “many masters” in drug development, patients, regulators, providers, and marketers, Dr. Krause shares insights on how to keep the patient at the center while driving innovation forward.Topics include:Lessons learned moving from big pharma to start-upsThe evolving relationship between medical affairs and clinical developmentBalancing regulatory, commercial, and patient prioritiesWhy knowing what you don't know is key to success in smaller companiesListen to this episode of Fractals: Life Science Conversations wherever you get your podcasts—and connect with Bracken to learn how we support drug development from concept to approval.

Dans cette édition :Israël affirme avoir frappé plus de 150 cibles depuis le lancement de son opération terrestre à Gaza, dans le cadre d'une offensive militaire majeure pour anéantir les terroristes du Hamas.En France, entre 800 000 et 1 million de manifestants sont attendus dans la rue demain pour dénoncer les mesures budgétaires annoncées cet été, avec la présence de groupuscules d'ultra-gauche qui viendraient casser, selon le ministre de l'Intérieur.Le laboratoire pharmaceutique britannique GSK va investir 30 milliards de dollars sur 5 ans aux États-Unis, dans le cadre d'un premier gros contrat annoncé lors de la visite d'État de Donald Trump au Royaume-Uni.Le maire de Barcelone refuse la présence de l'équipe israélienne Premier Tech au départ du Tour de France l'été prochain, qui sera donné depuis la ville catalane, après que cette équipe a été visée à plusieurs reprises par des manifestants pro-palestiniens lors de la Vuelta.Le coût des cotisations d'assurance va de nouveau augmenter l'année prochaine pour faire face à la hausse des aléas climatiques et des émeutes, selon le patron de la Maïf.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :L'accord migratoire franco-britannique entre en application avec l'arrivée du premier migrant renvoyé par le Royaume-Uni, la France proposant une aide au retour volontaire aux migrants.Les villes de Gravelines et Grande-Synthe font face à un afflux de migrants, saturant les transports en commun et perturbant la scolarité des élèves.La pétition de Philippe de Villiers pour un référendum sur l'immigration recueille près d'un million et demi de signatures.Israël annonce l'ouverture d'une nouvelle route de passage temporaire pour l'évacuation des habitants de la ville de Gaza, la France condamnant cette "campagne destructrice".Le laboratoire pharmaceutique britannique GSK va investir 30 milliards de dollars sur 5 ans aux États-Unis suite à un contrat avec Donald Trump.La France s'apprête à vivre une journée de grève massive jeudi avec des perturbations dans les transports et l'éducation, avec la crainte de la présence de black blocs violents.Le nouveau Premier ministre Sébastien Lecornu prépare son budget, les Républicains étant prêts à accepter des hausses d'impôts ciblées sur les plus riches.Le PSG affronte Bergame en Ligue des champions, privé de plusieurs joueurs blessés dont Ousmane Dembélé, favori pour le prochain Ballon d'Or.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

On The Down Low – Season 2: it's time to start talking about uterine cancersThe body often whispers before it screams — and recognising those early whispers can save lives. In this episode, we explore the importance of listening to symptoms like abnormal bleeding, and the role of risk factors such as obesity, hormones, lifestyle, and genetic predispositions including Lynch Syndrome. Through lived experience stories from Carly and Ruth, and expert insights from Professor Alison Brand AM, we uncover how prevention, risk assessment, and early diagnosis can change the future of uterine cancers.Know someone who needs to hear this? Share it, talk about it, and help break the silence around uterine cancers.Season 2 was produced by ANZGOG, with the generous support of GSK and Eisai.

Dans cette édition :L'accord migratoire franco-britannique entre en application avec l'arrivée du premier migrant renvoyé par le Royaume-Uni, la France proposant une aide au retour volontaire aux migrants.Les villes de Gravelines et Grande-Synthe font face à un afflux de migrants, saturant les transports en commun et perturbant la scolarité des élèves.La pétition de Philippe de Villiers pour un référendum sur l'immigration recueille près d'un million et demi de signatures.Israël annonce l'ouverture d'une nouvelle route de passage temporaire pour l'évacuation des habitants de la ville de Gaza, la France condamnant cette "campagne destructrice".Le laboratoire pharmaceutique britannique GSK va investir 30 milliards de dollars sur 5 ans aux États-Unis suite à un contrat avec Donald Trump.La France s'apprête à vivre une journée de grève massive jeudi avec des perturbations dans les transports et l'éducation, avec la crainte de la présence de black blocs violents.Le nouveau Premier ministre Sébastien Lecornu prépare son budget, les Républicains étant prêts à accepter des hausses d'impôts ciblées sur les plus riches.Le PSG affronte Bergame en Ligue des champions, privé de plusieurs joueurs blessés dont Ousmane Dembélé, favori pour le prochain Ballon d'Or.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dans cette édition :Israël affirme avoir frappé plus de 150 cibles depuis le lancement de son opération terrestre à Gaza, dans le cadre d'une offensive militaire majeure pour anéantir les terroristes du Hamas.En France, entre 800 000 et 1 million de manifestants sont attendus dans la rue demain pour dénoncer les mesures budgétaires annoncées cet été, avec la présence de groupuscules d'ultra-gauche qui viendraient casser, selon le ministre de l'Intérieur.Le laboratoire pharmaceutique britannique GSK va investir 30 milliards de dollars sur 5 ans aux États-Unis, dans le cadre d'un premier gros contrat annoncé lors de la visite d'État de Donald Trump au Royaume-Uni.Le maire de Barcelone refuse la présence de l'équipe israélienne Premier Tech au départ du Tour de France l'été prochain, qui sera donné depuis la ville catalane, après que cette équipe a été visée à plusieurs reprises par des manifestants pro-palestiniens lors de la Vuelta.Le coût des cotisations d'assurance va de nouveau augmenter l'année prochaine pour faire face à la hausse des aléas climatiques et des émeutes, selon le patron de la Maïf.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode, Sandra Peat sits down with Anna Hale, Chief Marketing Officer at Karo Healthcare, to explore her "excitement journey" through the world of brand building, transformation and purposeful marketing.From early beginnings at Reckitt to a 15-year career with GSK (now Haleon), Anna shares the pivotal moments that shaped her marketing philosophy—balancing emotional resonance with functional efficacy.  Now at Karo Healthcare, Anna discusses how the company is redefining modern brand-building in consumer health, from digitally-led strategies to AI-enhanced content creation. She talks about competing with scale by being smarter—not louder—and how Karo is helping people take ownership of their health in areas like women's intimate care and eczema treatment.The conversation explores how to build performance through people, the emotional power of “low involvement” brands, why purpose in consumer health is not optional—it's inherent and of course the evolving role of AI in marketing, from insight to execution.Tune in and get excited about the future of healthcare marketing and much more.

Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) Microsoft, OpenAI and other American companies announced plans to spend tens of billions of dollars on technology infrastructure in the UK, part of a series of business deals that coincide with President Donald Trump’s visit to the nation this week. (2) British drugmaker GSK pledged to invest $30 billion in the US over the next five years, making the announcement as President Donald Trump arrives in the UK for a highly anticipated state visit. (3) The euro hit its strongest level in four years as traders prepared for an interest-rate cut from the Federal Reserve this week that will cement its diverging trajectory from the European Central Bank. (4) TikTok’s US operations would be acquired by a consortium that includes Oracle, Andreessen Horowitz and private equity firm Silver Lake Management under a deal President Donald Trump is set to discuss with Chinese President Xi Jinping this week. (5) Europe’s top business lobby in China urged Beijing to address price wars and unsustainable competition as the country readies its next five-year plan — adding to pressure from the US over the matter. (6) The cyberattack that’s brought Jaguar Land Rover Automotive Plc factories to a standstill is affecting suppliers, with some European parts makers forced to pause or scale back their own production. Podcast Conversation: CEOs Win Over Trump With a Trophy, Prizes and Bragging RightsSee omnystudio.com/listener for privacy information.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough (RCC) is a debilitating condition that is often misunderstood and underdiagnosed, leaving patients with persistent symptoms despite standard treatment. Hear from Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss as they clarify the definition of RCC, outline essential diagnostic steps, and review current and emerging management strategies. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice and Operation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough can persist for years despite guideline-based therapy, significantly affecting patients' physical, social, and psychological wellbeing. Leading experts Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss explain how to distinguish RCC from other types of chronic cough, outline effective diagnostic strategies, and explore emerging treatment options. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and the Associate Chief of Clinical Research and Practice Innovation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

In the final episode of ‘Pull up a Chair' series three, Bina is joined by Sir Jon Symonds, Chair of GSK. Jon was Bina's first guest when the podcast launched in 2022, and together they reflect on what's happened in those three years – geopolitically, economically and technologically – and explore why Jon believes now is the most difficult time businesses are facing.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. During a Senate hearing, Robert F. Kennedy Jr. faced criticism for spreading anti-vaccine views and breaking promises regarding vaccines. The FDA released rejection letters for companies like Lykos Therapeutics, Stealth Biotherapeutics, and Regeneron. Ousted CDC director Susan Monarez accused Kennedy of firing her for not supporting Covid-19 recommendations from an advisory panel with "antivaccine rhetoric." Hengrui Pharmaceuticals signed lucrative deals with Merck and GSK, while the FDA promised to release future Complete Response Letters promptly. In other news, Sanofi's anti-OX40 blocker failed in a Phase III study, Gilead partnered with the US State Department for low-income countries, and AC Immune announced workforce cuts. Kennedy was accused of lying during the hearing, and the FDA released a new rare disease approval framework.

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Download the transcript here

Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option.   Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well."  #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer  actuatetherapeutics.com Listen to the podcast here

In this Healthed lecture, Professor Hubertus Jersmann will explain, spirometry, as done in general practice, enables accurate and early detection of COPD, and could be utilised more often to identify the many people who have this condition but remain undiagnosed or misdiagnosed. In addition, he will present the practical considerations of performing spirometry in the primary care setting - the logistics, the contraindications, the interpretation of results as well as common pitfalls and challenges. This educational activity was developed by Healthed at the request of and with funding from GSK.See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Ready to transform your HR operations?Download Deel's free AI-powered HR guide and discover how to streamline processes, stay compliant, and scale globally with ease: https://shorturl.at/Y1ySBWhy do toxic workplaces thrive, and how can leaders turn them around? In this HR L&D Podcast episode, we're sitting down with Dr Mary-Clare Race, a workplace psychologist and leadership expert, to uncover the psychology of toxic cultures and the strategies that transform them into thriving, inclusive environments.From her PhD research to leading DE&I initiatives for companies like Barclays, GSK, and Unilever, Dr Race explains why harmful behaviors persist, how to rebuild belonging, and why empathy, resilience, and self-awareness are the hallmarks of great leadership. She shares practical ways to hold leaders accountable, strengthen workplace connection, and use AI as a tool to support human-centered coaching.Whether you're in HR or lead a team, this conversation delivers actionable insights for creating healthier, more productive workplaces.Dr Mary-Clare Race's LinkedIn: https://www.linkedin.com/in/dr-mary-clare-race-b59a602/Nick Day's LinkedIn: https://www.linkedin.com/in/nickday/Find your ideal candidate with our job vacancy system: https://jgarecruitment.ck.page/919cf6b9eaSign up to the HR L&D Newsletter - https://jgarecruitment.ck.page/23e7b153e7(00:00) Why Human Resources Matter Most (01:46) Introducing Dr Mary-Clare Race (04:00) The Psychology of Workplace Toxicity (06:06) The “Toxic Triangle” Explained (07:48) Turning Toxic Cultures Into Thriving Ones (10:40) Why DE&I Slips During Economic Pressure (13:16) The Backlash Against DE&I (15:12) Building Belonging Through Human Connection (16:45) Remote Work's Impact on Toxicity (18:27) The Connection Crisis at Work (22:19) Do Playground Bullies Become Business Leaders? (26:25) How Early Experiences Shape Leadership Styles (28:56) Empathy, Resilience & Self-Awareness in Leadership (31:46) Micro-Coaching Moments for Busy Leaders (33:30) Leading Multi-Generational Workforces (36:42) Supporting Caregivers and Working Parents (39:26) AI in Coaching and Leadership Development (43:45) Final Advice for HR Leaders

This week's deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunities being fostered in China — and how it's no longer all about fast followers.On the latest BioCentury This Week podcast, BioCentury's analysts put the collaboration between GSK and Jiangsu Hengrui Pharmaceuticals, two of the most active cross-border dealmakers, into the context of East-West dealmaking over the past 30 months, assessing the innovation that is driving the rush to partner with biotechs in China, Japan, South Korea and beyond, and the types of companies looking to Asia for assets.BioCentury's analysts also discuss Steve Bates' outsized role in building the U.K. biotech hub, as he readies to take on a new role in the U.K. government. They examine new VC funds from Omega Funds and Brandon Capital, FDA's new national priority voucher pilot program, and fallout from how FDA and  Sarepta Therapeutics handled the deaths of four patients who had received the biotech's gene therapies. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656592#biotech #biopharma #pharma #lifescience #EastWestDealmaking #ChinaBiotech #UKBiotech #FDAPolicy00:01 - Sponsor Message: IQVIA Biotech02:48 - Asia Deals Landscape17:32 - Steve Bates & U.K. Biotech25:46 - FDA's New Voucher Pilot31:01 - New VC Funds35:28 - SareptaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text